Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents

Overview

Journal Dermatology

Publisher Karger

Specialty Dermatology

Date 2020 Jan 21

PMID 31958794

Citations 9

Authors

Antonio Torrelo

Ramon Grimalt

Xavier Masramon

Nuria Albareda Lopez

Ilonka Zsolt

Affiliations

Soon will be listed here.

Abstract

Background: Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group.

Methods: Pooled data for patients aged 6 months to <18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5-<2, 2-<6, 6-<12, and 12-<18 years.

Results: The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (n = 239), vehicle (n = 201), or retapamulin as internal validation control (n = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days' treatment (day 6-7, end of therapy), and microbiological success rates after 3-4 days' treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (p < 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption.

Conclusion: This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years.

Citing Articles

Green Nail Syndrome Treated with Ozenoxacin: Two Case Reports.

Cosio T, Petruccelli R, Gaziano R, Fontana C, Favaro M, Zampini P Case Rep Dermatol. 2023; 15(1):217-224.

PMID: 38023344 PMC: 10653707. DOI: 10.1159/000533923.

Staphylococcal Infections and Neonatal Skin: Data from Literature and Suggestions for the Clinical Management from Four Challenging Patients.

De Rose D, Pugnaloni F, Martini L, Bersani I, Ronchetti M, Diociaiuti A Antibiotics (Basel). 2023; 12(4).

PMID: 37106994 PMC: 10135205. DOI: 10.3390/antibiotics12040632.

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?.

Rusu A, Munteanu A, Arbanasi E, Uivarosi V Pharmaceutics. 2023; 15(3).

PMID: 36986665 PMC: 10056716. DOI: 10.3390/pharmaceutics15030804.

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.

Shi Z, Zhang J, Tian L, Xin L, Liang C, Ren X Molecules. 2023; 28(4).

PMID: 36838752 PMC: 9962477. DOI: 10.3390/molecules28041762.

Targeted Isolation of Antibiotic Brominated Alkaloids from the Marine Sponge Using Virtual Screening and Molecular Networking.

Lever J, Kreuder F, Henry J, Hung A, Allard P, Brkljaca R Mar Drugs. 2022; 20(9).

PMID: 36135743 PMC: 9503778. DOI: 10.3390/md20090554.

References

Gropper S, Albareda N, Chelius K, Kruger D, Mitha I, Vahed Y . Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol. 2014; 9(9):1013-23. DOI: 10.2217/fmb.14.78. View

Rortveit S, Skutlaberg D, Langeland N, Rortveit G . The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway. Scand J Infect Dis. 2014; 46(12):832-7. PMC: 4266085. DOI: 10.3109/00365548.2014.947317. View

Gropper S, Cepero A, Santos B, Kruger D . Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo. Future Microbiol. 2014; 9(8 Suppl):S33-40. DOI: 10.2217/fmb.14.85. View

Sareyyupoglu B, Ozyurt M, Haznedaroglu T, Ardic N . Detection of methicillin and mupirocin resistance in staphylococcal hospital isolates with a touchdown multiplex polymerase chain reaction. Folia Microbiol (Praha). 2008; 53(4):363-7. DOI: 10.1007/s12223-008-0056-4. View

van Bijnen E, Paget W, den Heijer C, Stobberingh E, Bruggeman C, Schellevis F . Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureus in the community. BMC Fam Pract. 2014; 15:175. PMC: 4220054. DOI: 10.1186/s12875-014-0175-8. View

Bowen A, Mahe A, Hay R, Andrews R, Steer A, Tong S . The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One. 2015; 10(8):e0136789. PMC: 4552802. DOI: 10.1371/journal.pone.0136789. View

Rosen T, Albareda N, Rosenberg N, Alonso F, Roth S, Zsolt I . Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018; 154(7):806-813. PMC: 6128489. DOI: 10.1001/jamadermatol.2018.1103. View

Lopez Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Canton R . In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2013; 57(12):6389-92. PMC: 3837899. DOI: 10.1128/AAC.01509-13. View

Rossney A, OConnell S . Emerging high-level mupirocin resistance among MRSA isolates in Ireland. Euro Surveill. 2008; 13(14). View

10.

Sladden M, Johnston G . Current options for the treatment of impetigo in children. Expert Opin Pharmacother. 2005; 6(13):2245-56. DOI: 10.1517/14656566.6.13.2245. View

11.

Gropper S, Albareda N, Santos B, Febbraro S . Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers. Future Microbiol. 2014; 9(8 Suppl):S11-6. DOI: 10.2217/fmb.14.82. View

12.

Gonzalez Borroto J, Awori M, Chouinard L, Smith S, Tarrago C, Blazquez T . Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs. Future Microbiol. 2018; 13:31-40. DOI: 10.2217/fmb-2017-0291. View

13.

Denton M, OConnell B, Bernard P, Jarlier V, Williams Z, Santerre Henriksen A . The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland. J Antimicrob Chemother. 2008; 61(3):586-8. DOI: 10.1093/jac/dkm531. View

14.

Desroches M, Potier J, Laurent F, Bourrel A, Doucet-Populaire F, Decousser J . Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. J Antimicrob Chemother. 2013; 68(8):1714-7. DOI: 10.1093/jac/dkt085. View

15.

Canton R, Morrissey I, Vila J, Tato M, Garcia-Castillo M, Lopez Y . Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates. Future Microbiol. 2018; 13:3-19. DOI: 10.2217/fmb-2017-0289. View

16.

Gropper S, Cepero A, Dosik J, LaStella P, Siemetzki H, Wigger-Alberti W . Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers. Future Microbiol. 2014; 9(8 Suppl):S23-31. DOI: 10.2217/fmb.14.84. View

17.

Doudoulakakis A, Spiliopoulou I, Spyridis N, Giormezis N, Kopsidas J, Militsopoulou M . Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections. J Clin Microbiol. 2017; 55(8):2529-2537. PMC: 5527431. DOI: 10.1128/JCM.00406-17. View

18.

Castanheira M, Watters A, Mendes R, Farrell D, Jones R . Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J Antimicrob Chemother. 2010; 65(7):1353-8. DOI: 10.1093/jac/dkq094. View

19.

Alsterholm M, Flytstrom I, Bergbrant I, Faergemann J . Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol. 2010; 90(1):52-7. DOI: 10.2340/00015555-0771. View

20.

Vila J, Hebert A, Torrelo A, Lopez Y, Tato M, Garcia-Castillo M . Ozenoxacin: a review of preclinical and clinical efficacy. Expert Rev Anti Infect Ther. 2019; 17(3):159-168. DOI: 10.1080/14787210.2019.1573671. View